The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Regorafenib dose escalation therapy for patients with refractory metastatic colorectal cancer (RECC Study).
 
Masato Nakamura
Honoraria - Bayer; Bayer; Bayer; Bayer; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Takeshi Yamada
Research Funding - Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Shun Ishiyama
No Relationships to Disclose
 
Masanobu Enomoto
No Relationships to Disclose
 
Hajime Yokomizo
No Relationships to Disclose
 
Chihiro Kosugi
No Relationships to Disclose
 
Hiromichi Sonoda
No Relationships to Disclose
 
Kei Ishimaru
No Relationships to Disclose
 
Keiichiro Ishibashi
No Relationships to Disclose
 
Hidekazu Kuramochi
No Relationships to Disclose
 
Keijiro Nozawa
No Relationships to Disclose
 
Ryo Ohta
No Relationships to Disclose
 
Makoto Takahashi
No Relationships to Disclose
 
Hiroshi Yoshida
No Relationships to Disclose
 
Yojiro Hashiguchi
Honoraria - Bayer; Bayer; Bayer; Bayer; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Kaken Pharmaceutical; Kaken Pharmaceutical; Kaken Pharmaceutical; Kaken Pharmaceutical; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Kaken Pharmaceutical (Inst); Kaken Pharmaceutical (Inst); Kaken Pharmaceutical (Inst); Kaken Pharmaceutical (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Keiji Hirata
No Relationships to Disclose
 
Kenji Katsumata
No Relationships to Disclose
 
Hideyuki Ishida
No Relationships to Disclose
 
Keiji Koda
No Relationships to Disclose
 
Kazuhiro Sakamoto
No Relationships to Disclose